

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Cancer Stem Cells in Multiple Myeloma

Sabino Ciavarella, Annalisa Milano, Annalisa Savonarola,
Oronzo Brunetti, Franco Dammacco and Franco Silvestris
*University of Bari "A. Moro" /Department of Biomedical Science and Clinical Oncology
Italy*

1. Introduction

Over the last few years, the hypothesis that rare stem cell-like cells are responsible for tumor initiation and maintenance, namely the cancer stem cell (CSC) theory, has remarkably changed the way to approach cancer biology. The scientific relevance of this theory is based, in fact, not only on the existence of hierarchically organized, self-renewing malignant progenitor cells within each tumor, but also on the assumption that their drug resistance may account for the high frequency of relapse that renders incurable most tumors despite their treatment with specific cytotoxic drugs. The view that CSCs may descend from normal stem cells finds its historical background in studies on acute myeloid leukemia where the leukemic clone is organized according to a defined hierarchy in which the majority of tumor cells rapidly proliferate, while quiescent "leukemic stem cells" resembling early hematopoietic progenitors remain as a potential reservoir of cancer propagation due to their chemoresistance to specific cytotoxic protocols.

Recently, however, a large number of studies have turned the CSC theory into more than an idea, since clear experimental evidence has demonstrated the existence of CSCs in a number of tumors. Indeed, brain (Singh et al., 2004), intestinal (O'Brien et al., 2007) and breast cancers (Al-Hajj et al., 2003) have been shown to arise from rare cells, organized in a precise hierarchy resembling that of stem cells, which are capable of generating a differentiated progeny by repetitive asymmetric divisions. In most of these tumors, however, the earliest event driving the malignant transformation remains elusive and the original cell is far from being defined, since both histological and cell-surface marker profiles of the bulk tumor cells do not necessarily resemble those of the lineage-related stem cell. These observations, moreover, have been interpreted to suggest that CSCs could derive either from normal stem cells or from committed progenitor cells that have acquired the ability to self-renew due to specific genetic mutations (Visvader, 2011).

Similar controversies have arisen with hematological malignancies of both myeloid and lymphoid origin, including multiple myeloma (MM). In fact, differently from acute leukemia, in the initial phases of most chronic lymphoproliferative disorders, neoplastic cells do not resemble early hematopoietic stem cells, but rather cellular elements in late maturation phases, as clearly demonstrated in chronic myeloid leukemia (Jamieson et al., 2004). In MM, malignant plasma cells are characterized by unique patterns of immunoglobulin (Ig) and surface antigen expression, thus suggesting that the tumor bulk is exclusively composed of terminally differentiated cells with high proliferation potential.

However, the evidence that the majority of MM cells are quiescent and that, similarly to their normal counterpart, they lack long-lasting proliferation potential both *in vitro* and *in vivo* (Dewinko et al., 1981) implies that tumor growth is actually dependent on a more restricted subset of clonogenic and self-renewing lymphoid cells. Thus, based on the observation that both blood and bone marrow (BM) from MM patients contain lymphoid elements with a hypervariable region Ig gene repertoire identical to that of bulk tumor cells, it has been hypothesized that part of the hierarchical model of the lymphoid lineage maturation may recur also in MM (Pilarski & Jensen, 1992; Billadeau et al., 1993). The functional heterogeneity of tumor cells in MM provides the rationale for exploring the coexistence of bulk plasma cells and putative tumor stem cells resembling both phenotype and biological characteristics of B lymphocytes, consistent with the similarity observed between hematopoietic progenitors and tumor cells in leukemia. To date, several studies have highlighted the existence of putative myeloma CSCs that share with normal adult stem cells a number of molecular and functional aspects, including their resistance to conventional treatments (Agarwal & Matsui, 2010). Therefore, although issues such as CSC origin, phenotype and potential pathogenetic role in MM are still being debated, investigating MM CSCs may provide new molecular targets for treatment of this still incurable disease.

2. Implication of the CSC theory in MM pathogenesis: from “clonotypic B cells” to putative MM CSCs

Major clinical manifestations of MM, including anemia, skeletal impairment, hypercalcemia and renal failure, are related to the progressive accumulation of malignant plasma cells within BM. Moreover, similarly to normal plasma cells, malignant plasma cells produce Ig as the monoclonal component commonly detectable in serum and urine of MM patients. But as early pathogenetic events, including key oncogenic mutations, occur during B cell maturation, MM is regarded as a B cell malignancy rather than a plasma cell neoplasm.

Normal plasma cells derive from “post-germinal center B cells” (PGBCs) that have completed a program of somatic hypermutations following the Ig heavy chain (IgH) switching in lymph nodes, and undergone the subsequent maturation in circulating “memory B cells” that migrate to BM, where the stromal microenvironment drives their terminal differentiation at both morphological and functional level (Johnson et al., 2005). In this context, a recent model of myelomagenesis (Anderson & Carrasco, 2011) postulates that malignant plasma cells derive from B cells of the lymph node post-germinal center, since they display an identical pattern of hypermutated Ig genes within their clone. It is thus conceivable that a PGBC likely undergoes a first oncogenic mutation, giving rise to a clone of premalignant B cells expressing identical Ig genes and capable of migrating to BM. Therefore, the asymptomatic phase of MM development, namely monoclonal gammopathy of undetermined significance (MGUS), may be sustained by the emergence within BM of only a limited number of malignant plasma cell clones producing monoclonal Ig. Subsequent changes within marrow milieu, including induction of angiogenesis, development of cytokine-based paracrine signalling loops, and acquisition of additional genetic mutations by tumor cells, are thought to promote further growth of malignant plasma cells, thus definitely mediating the switch from MGUS to MM.

Early investigations revealed that peripheral blood of both MGUS and MM patients contains a large fraction of circulating B cells at a late stage of differentiation, as proven by their

minor CD19 and CD20 expression (Jensen et al., 1991). Although morphologically heterogeneous, these cells display identical Ig gene rearrangements in support of their monoclonal derivation and, of note, expressed the same type of either kappa or lambda light chain mRNA of BM plasma cells (Jensen et al., 1992). In parallel studies, these “clonotypic B cells” (CBCs) were found to even express typical plasma cell antigens, such as the plasma cell membrane glycoprotein-1 (PCA-1) and CD38, variable levels of CD11b β 2-integrin, CXCR4 and CXCR5, pivotal molecules for the homing to BM, while lacking CD34 as typical marker of the hematopoietic stem cell subset (Jensen et al., 1992). Subsequent investigations, moreover, have demonstrated that the number of CBCs is variable among patients with an average value of 65% of peripheral B cells, although they equally express identical IgH rearrangements as parental BM myeloma cells (Bergsagel et al., 1995), that has been confirmed by gene sequencing analyses (Berenson et al., 1995; Szczyepc et al., 1998). Thus, in order to identify the actual differentiation state of circulating CBCs, a number of studies were aimed at assessing the CD45 expression level, since normal B cells usually lose CD45 antigen as their maturation progresses. CBCs display different patterns of CD45 expression, depending on their location, ranging from higher levels when they reside in proximity to secondary lymphoid organs to minor expression in either BM or peripheral blood (Jensen et al., 1992). Interestingly, in a single previous report, clonal circulating B cells from MM patients were found to resemble the memory B cell phenotype (Rasmussen et al., 2004), thus suggesting that CBCs could represent an ongoing differentiating population (from PGBCs to plasmablasts) in MM, and that they may play a pivotal role in MM pathogenesis. These cells may originate in peripheral lymphoid system and, once having undergone key oncogenic mutations, migrate toward the BM to complete their differentiation into malignant plasma cells (Pilarski & Jensen, 1992).

In spite of their malignant nature, myeloma cells seem to resemble their normal counterpart at both phenotypic and functional level. Examination of BM biopsies from MM patients commonly reveals the infiltration of cells expressing the typical mature plasma cell marker CD138. They appear relatively quiescent (Kyle & Rajkumar, 2004), and, similarly to their terminally differentiated normal counterpart, display low proliferative index (Robillard et al., 2005). Other early experiments using murine MM cells showed that only a small proportion of malignant plasma cells are able to form single cell-derived colonies either in vitro or in vivo (Bergsagel & Valeriote, 1968; Canc Res; Park et al., 1971), thus emphasizing that both clonogenic and proliferation potential are restricted to a small fraction of neoplastic cells. Subsequent observations underscored that, similarly to murine MM, human malignant plasma cells possess low colony-forming capacity and only rare cells within tumor clone give rise to colonies in vitro (Hamburger & Salmon, 1977).

Evidence of a functional heterogeneity in MM is also supported by other clinical observations. Today, treatment of MM with steroids, alkylating drugs, immunomodulatory agents, proteasome inhibitors and stem cell transplantation (SCT) procedures induces improvement of median survival of patients but does not provide potential for cure, due to the high rate of MM relapse after treatment. Taken together, these observations suggest that only a small fraction of tumor cells possess the capability of initiating tumor growth and, similar to stem cell behavior within normal tissues, this small fraction is able to rebuild and maintain the original MM clone after therapy.

CBCs obtained from peripheral blood of patients with MM have been shown to successfully engraft into immunocompromised mice and induce major clinical features of human MM, such as osteolytic lesions and the production of a serum monoclonal component (Pilarski et

al., 2000). These cells, moreover, possess slight sensitivity to current anti-MM agents. It has also been demonstrated that the majority of monoclonal B cells from patients with MM show high levels of P-glycoprotein which is involved in the multi-drug resistance, and that they increase its expression after chemotherapy (Pilarski & Belch, 1994). High levels of circulating CBCs have been found during transient post-treatment remissions, and patients undergoing disease progression or relapse showed larger fractions of CBCs than those responding to treatment as well as untreated patients (Bergsagel et al., 1995). Furthermore, given the high occurrence of disease relapse after auto-SCT, it is conceivable that even high-dose chemotherapy regimens used during conventional SCT procedures is not enough to eliminate CBCs or, alternatively, that CBCs are being collected during leukapheresis and, once transplanted to patient, are able to drive the tumor relapse.

Taken together, these observations support a new model of MM pathogenesis in which CBCs, as clonogenic, self-renewing, and drug resistant cells belonging to the original malignant cell clone, may also represent the malignant stem cell population in MM (Fig. 1).




Fig. 1. Cancer stem cells in a proposed model of MM pathogenesis

In the germinal center of lymph nodes, healthy B lymphocytes physiologically undergo antigen selection and give rise to different clones of post-germinal B cells that have successfully completed sequential rounds of somatic hypermutations and Ig gene recombination. Each post-germinal B cell clone may produce memory B cells possessing consistent pattern of hypermutations within their own clone. These cells progress along their differentiation course and migrate, as plasmablasts, to BM where the stromal environment induces their terminal maturation into functional plasma cells capable of secreting Ig. A first oncogenic mutation may hit a post germinal center B cells, giving rise to

a clone of pre-malignant circulating B lymphocytes expressing identical Ig genes (clonotypic MM B cells). These cells, however, may retain their stem cell properties (self-renew and differentiation) and, once migrated to BM, divide by asymmetric divisions that can generate malignant plasma cells and a reservoir of MM stem cell fraction (MGUS). Presumably, the malignant plasma cell population may acquire additional mutations and expand by symmetric divisions. Other BM factors, including neoangiogenesis and formation of a variety of paracrine signalling loops with stromal BM components, may further support MM cell growth, whereas a little proportion of clonotypic MM stem cells with tumor-initiation capacity, persist within tumor mass.

2.1 Biological properties of MM CSCs: searching for the putative myeloma stem cell phenotype

In a number of both hematologic and solid malignancies, including acute myeloid leukemia and brain tumors, identification of CSCs was accomplished by searching the lineage-specific antigens of respective progenitors (Bonnet & Dick, 1997; Singh et al., 2004), and by their capacity to engraft into murine immunodeficient mice and recapitulate the disease. Similarly, based on the accredited theory that bulk malignant myeloma cells arise from asymmetric divisions of rare elements belonging to the B cell lineage, it has been prospectively assumed that the MM CSC population should lack CD38 and CD138 antigens, and display high self-renewal and myelomagenic potential both *in vitro* and *in vivo*.

In the first animal model engrafted with primary human myeloma cells, BM specimens from MM patients were directly injected in fetal bone chips subcutaneously implanted in SCID mice (Yacoby et al., 1998). This model resembled several features of human MM, including the occurrence of the circulating monoclonal component, hypercalcemia and the typical MM-associated bone disease. Subsequent studies revealed that the tumor bulk is the effect of the growth of plasma cells expressing CD38, while lacking CD45 and showing high self-renewing capacity as proven by their ability to engraft into the secondary SCID-hu recipient. On the contrary, no proliferation was ascribed to the cell fraction containing CD19⁺ B cells (Yacoby et al., 1999). These data, however, were in apparent contrast with the knowledge that, at least *in vitro*, the clonogenic frequency of primary malignant cells was as low as 0.1% (Hamburger & Salmon, 1977), although it is conceivable that microenvironmental factors within the SCID-hu bone chips might support the growth of CD38⁺ plasma cells. On the other hand, peripheral blood-derived CD19⁺ clonotypic B cells from a patient with progressive MM were shown to successfully engraft into immunodeficient mice and produce tumor bulks mostly composed by CD19⁺/CD138⁺ malignant cells (Pilarski et al., 2002). These findings were in agreement with the previous observation showing that NOD/SCID mice are good recipients for the engraftment of circulating B cells from MM patients developing myeloma masses predominantly composed of CD38⁺ and CD19⁺ cells (Pilarski et al., 2000). The latter studies also emphasized that clonotypic B cells, rather than CD138⁺ malignant plasma cells, are directly involved in tumor formation, although the proof that clonogenic B cells have self-renewal potential is still missing, since no serial transplantation has been performed in secondary animal hosts.

Based on these findings, initial studies comparing the ability of highly CD138⁺ myeloma plasma cells with CD138⁻ cells to form colonies *in vitro* revealed that cells lacking typical plasma cell markers showed higher clonogenic frequency and easy undergoing to serial passages *in vitro*. Accordingly, CD138⁺ cells were unable to engraft into NOD/SCID mice

when intravenously injected, whereas cells with B cell phenotype effectively engrafted in mice and produced tumor burdens of mature CD138⁺ plasma cells secreting the monoclonal Ig. In the same study, moreover, single cell-derived colonies capable of *in vivo* myelomagenesis were shown to contain variable amounts of cells expressing CD45, CD19, CD20 and CD27 as typical surface antigens of the memory B cells (Matsui et al., 2004). The concept that cells expressing markers of memory B cells share exclusive properties with normal stem cells further supported the derivation of the malignant plasma cell from a post-germinal cellular element. Consistently, although unable to undergo multilineage differentiation due to their committed state, memory B cells physiologically maintain the capacity to self-renew even during their maturation, thus ensuring the immune memory as a crucial requirement of adaptive immunity. Other independent groups, previously involved in exploring the role of B cells in MM development, showed that the gene repertoire encoding the monoclonal Ig component mostly occurred in B cells from both BM and peripheral blood rather than in mature plasma cells (Billadeau et al., 1993; Bakkus et al., 1994), albeit such a clonogenic B cell population can rarely be detected in primary biopsic specimens (0.1% of all tumor cells) (Chen & Epstein, 1996; Rasmussen, 2001).

In line with this view, blood and BM specimens from MM patients were shown to contain a CD138⁻/CD19⁺/CD20⁺/CD27⁺ cell fraction with higher clonogenic capacity as compared to the CD138⁺ cell counterpart. More interestingly, this memory B cell-like subpopulation was found to share identical Ig gene rearrangement as the malignant plasma cells and, unlike these, effectively engraft into NOD/SCID mice that develop plasmacytomas mostly composed of CD138⁺ cells clonally related to the injected cells by similar Ig light chain restriction (Matsui, 2004). In addition, small subsets of CD138⁻/CD19⁺/CD20⁺/CD27⁺ cells harvested from BM of the mice were successfully injected in secondary recipients that in turn developed MM (Matsui et al., 2008). These findings, in agreement with previous evidence of circulating memory B cells in MM patients (Rasmussen et al., 2004), suggest that the CD138⁻/CD19⁺/CD20⁺/CD27⁺ B cell subset may represent the putative CSC clone in MM (Clarke et al., 2006).

Despite these convincing data, many questions regarding the actual phenotype of the CSCs in MM remain unanswered, and new observations make this issue rather controversial. At present, several *in vivo* reproductions of MM have successfully utilized immunodeficient mice injected with CD138⁺ malignant plasma cells (Yaccoby & Epstein, 1999). Although empiric, these observations emphasize the ability of phenotypically mature tumor cells by themselves to recapitulate MM *in vivo*. In addition, further studies underscore the absence of MM cells clonal derivation from respective B cell precursors, since CD19⁺ cells from different patients were shown to express no tumor-specific genetic mutations (McSweeney et al., 1996). Finally, malignant plasma cells display high plasticity and are capable, after long-term interaction with other components of the BM microenvironment, to reprogram their gene array as well as to turn back to a more immature phenotype including low levels of CD19 but lacking both CD38 and CD138 molecules. In addition, these cells resemble the plasmablastic morphology, thus supporting a “de-differentiation” theory (Yaccoby, 2005) rather than the existence of a subset of CSCs within the MM bulk during early phase of its development. Fig. 2 shows the detection of putative CSCs in a representative bone biopsy from a patient with MM. As can be seen, in the context of a myeloma bone lesion including CD138 stained cells (black arrows), we found a minimal number of cells with typical plasmablast morphology and lacking the CD138 antigen that infiltrate a tumor mass mostly composed by CD138⁺ plasma cells.




Fig. 2. Representative immunohistochemical detection of CD138⁺ malignant plasma cells within MM bone marrow biopsy

MM bone marrow section showing high infiltration of cells with mature plasma cell morphology and intense positivity to CD138 staining (black arrows) that stand close to cellular elements with plasmablastic appearance lacking CD138 (red arrows).

2.1.1 Functional properties of MM CSCs

The property to undergo asymmetric divisions and give rise to more differentiated cells retaining high proliferative behavior is not the unique functional hallmark that MM CSCs share with their normal progenitor cells. In fact, similarly to stem cells of either leukemia or brain tumors (Lapidot et al., 1994; Singh et al., 2004), putative MM-initiating cells are resistant to toxic chemical injury, thus accounting for the common risk of disease relapse following conventional treatments. Long-term proliferating CD138⁻ cells, rather than both their CD138⁺ counterpart and myeloma cell lines, were shown to be slightly influenced in their survival and clonogenic capacities by exposure to common anti-MM agents, such as Dexamethasone, Lenalidomide and Cyclophosphamide (Matsui et al., 2008). Similarly, investigation in our laboratory demonstrated that primary CD138⁻ malignant plasma cells incubated with different concentration of the proteasome inhibitor Bortezomib reach higher survival rates as compared with the control CD138⁺ U-266 myeloma cell line (Fig. 3).

Cells were cultured for 48 hours with increasing concentrations of Bortezomib and evaluated by MTT assay for their viability. CD138⁻ MM cells show higher survival rates (red curve) as compared with CD 138⁺ U-266 cells (blue line).

Both normal stem cells and cancer cells have been intensively investigated for their drug resistance (Fletcher II et al., 2010). A few biological processes are commonly claimed to explain their scarce sensitivity to most cytotoxic agents and are typical of some tumors, including MM. When long-term cultured, in fact, putative MM CSCs predominantly stand in the G0-G1 cell cycle phase (Matsui et al., 2008), thus explaining why they appear poorly




Fig. 3. Bortezomib responsiveness of CD138⁻ MM cells and CD138⁺ U-266 MM cells

responsive to DNA-damaging compounds, such as alkylating agents. However, the drug resistance in MM CSCs seems to be mediated by additional mechanisms, such as the over-expression of the ATP-binding cassette family of drug transporters (ABCG2/BCRP), as well as the high levels of intracellular detoxification enzymes such as the aldehyde dehydrogenase (ALDH) (Matsui et al., 2008). Interestingly, each of these properties is currently used for cytometric assessment of CSCs for distinguishing the putative stem cell fraction within normal (Goodell et al., 1996) and tumor tissues (Sussman et al., 2007). In MM, as well as in other tumors, the capacity to export the nuclear dye Hoechst 33342, that identifies the so-called “side population” (SP), was recently evaluated on several CD138⁺ plasma cell lines resulting in the detection of a small proportion of SP cells lacking CD138 molecules within each cell line. These cells, moreover, expressed high levels of ALDH, emphasizing that the putative drug resistant myeloma stem cells exhibit a more immature phenotype than CD138⁺ bulk malignant plasma cells (Matsui et al., 2008). On the other hand, MM cell lines stained by Hoechst 33342 showed to mostly contain distinct SP subsets that, however, were variably expressing CD138. Interestingly, these SP fractions were found to lack CD19, CD20 and CD27 surface molecules, thus arguing against previous findings that emphasized the memory B cell phenotype of MM CSCs (Jakubikova et al., 2011).

2.1.2 Molecular aspects of MM CSC biology

Given their high clonogenicity, self-renewal and drug resistance, MM CSCs have been suspected to share exclusive pathways and molecular signals with normal adult stem cells. Wnt, Notch and Hedgehog (Hh), the most conserved developmental pathways in humans, are involved in normal stem cell self-renewing and differentiation following injury and, although dormant in most human tissues, they are aberrantly triggered in a variety of human cancers (Taipale et al., 2001; Ruiz I Altaba et al., 2002). In particular, other than being involved in cancer development (Duman-Scheel et al., 2002), Hh plays a pivotal role in CSC biology of different malignancies, including breast cancer, chronic myeloid leukemia and MM (Liu et al., 2006; Zhao et al., 2009; Agarwal et al., 2010). The surface receptor patched (PTCH), a transmembrane molecule, provides the starting point of Hh signalling cascade, whereas three different ligands, namely Sonic, Indian and Desert, bind PTCH in mammals. Once bound, PTCH de-represses a seven-transmembrane smoothed (SMO) protein which, in turn, regulates the activity of three GLI proteins that enhance the transcription of several cell cycle regulator genes (Duman-Scheel et al., 2002). Mutations of PTCH or SMO can thus

enhance the pathway activity and underlay the development of significant percentages of basal cell carcinomas and medulloblastomas (Gailani et al., 1996; Raffel et al., 1997). Interestingly, both human myeloma cell lines and primary MM cell preparations overexpress some Hh signalling components, while CD138⁺ MM stem cells from established tumor cell lines show higher levels of Sonic-Hh (SHh) signalling activity with respect to their differentiated counterpart (Peacock et al., 2007). Moreover, treatment with Sonic ligand results in a relevant expansion of MM CSC subsets and improves their clonogenic capacity by inhibiting the cell differentiation. By contrast, inhibition of SHh pathway in MM CSCs reduces their attitude to form colonies in vitro, thus suggesting their progressive differentiation. These data imply that a constitutive deregulation of SHh may contribute to the maintenance of undifferentiated CSC clones in MM, whereas other findings revealed that stromal cells, in the context of MM microenvironment, produce Hh ligands and may strongly impact on the survival of MM CSCs within their niches (Dierks et al., 2007).

MM CSCs exhibit other molecular aspects typical of normal stem cells. MM CSCs from both in vitro established MM cell lines and patients have been shown to possess high telomerase activity (Brennan et al., 2010). CD138⁺ cells from commercial cell lines, in fact, showed higher levels of telomerase activation than their differentiated counterpart, thus emphasizing the crucial role of telomerase activity in regulating several biologic processes, such as cellular senescence and apoptosis in normal adult progenitor cells as well as in growth and maintenance of most human cancers (Shay & Bacchetti, 1997). MM CSCs have also been described to overexpress mRNAs of OCT4, NANOG and SOX2, the major regulators of self-renewal and pluripotency of embryonic stem cells (Yu et al., 2009). In particular, OCT4 drives the major transcriptional networks during the embryonic development and, at the same time, the formation of pluripotent stem cells in the mammalian embryos (Nichols J, et al. 1998). In this context, we have detected OCT4 in CD138⁺ cells from the BM of patients with MM. As seen in Fig. 4, this transcription factor was dramatically overexpressed in these cells and, thus, it was interpreted as a marker of their stemness.




Fig. 4. Immunofluorescence analysis of OCT4 expression in MM stem cells

Fluorescence microscopy image showing a colony of putative MM stem cells stained for both cytoskeletal actin and OCT4 by falloidin (green) and anti-OCT4 PE-conjugated antibody (red), respectively. The typical ovoid shape of these cells is marked by the homogeneous distribution of cytoskeletal actin, whereas all nuclei are strongly positive for OCT4. The OCT4 signal is particularly intense at the nuclear periphery and originates red rings along nuclear contours.

Telomerase activity in MM CSCs, but not in bulk CD138⁺ plasma cell fraction, was described to parallel the expression of embryonic stem cell genes as Notch and Hh (Brennan et al., 2010). Inhibition of telomerase activity significantly strengthens its role in biology of MM CSCs, since long-term treatment with Imetelstat, a specific competitor of telomerase reverse transcriptase, dramatically reduces both the colony-forming ability of MM CSCs and their engraftment into immunodeficient mice. On the other hand, short-term telomerase inhibition fails to induce telomere shortening in MM CSCs, but relays with a relevant down-regulation of OCT4, NANOG and SOX2 expression, resulting in parallel decrease of their clonogenicity. Therefore, it is becoming clear that specific genes and transcriptional factors driving normal stem cell fate may also affect the functions of MM CSCs and, at the same time, provide potential therapeutic targets in MM.

2.2 Targeting MM CSCs: Implication in MM treatment

For many years, the alkylator-based treatment schedules have represented the most used options for MM, due to their ability to induce prompt responses and symptom improvement (Oken et al., 1997). However, the median survival of patients treated with conventional drugs rarely exceeds 3 years and the disease commonly relapses or shortly progresses after treatment. On the other hand, either autologous or allogeneic hematopoietic stem cell transplantations induce extension of the disease-free survival, but not of the overall survival, in a small group of patients (Bensinger, 2002; Koreth et al., 2007), while a high rate of mortality may occur in allogeneically transplanted patients. Based on their effectiveness in inducing significant prolongation of disease-free survival, novel classes of agents, including immunomodulatory compounds, such as Thalidomide and Lenalidomide, the proteasome inhibitor Bortezomib, and new alkylating molecules such as Bendamustin (Cheson, 2010; Lonial et al., 2011), have recently entered into the spectrum of anti-MM treatments, although they also fail to provide long-lasting remissions and their real improvement of overall survival is still to be accurately assessed.

These clinical observations further support the “CSC hypothesis” in MM, suggesting that tumor burden may be actually composed of a biologically heterogeneous cell population containing two subsets of cancer cells with different drug responsiveness, namely: i) terminally differentiated plasma cells with short doubling time and chemotherapy sensitivity; ii) quiescent stem cells with intrinsic drug resistance and the ability to self-renew that drive both disease relapse and progression. In this view, the development of strategies aimed at selectively eradicating the stem cell-like cell population offers a real perspective to achieve long-term remissions in MM. Thus, these novel strategies include: i) targeting specific pathways of CSCs, such as SHh pathway; ii) inhibition of the telomerase activity; and iii) induction of CSC differentiation (Tab. 1).

2.2.1 Targeting developmental signalling pathways

Given the exclusive role of SHh pathway in the pathobiology of MM CSCs, development of specific inhibitors of SHh signalling components, such as PTCH, SMO and GLI proteins, has

been strongly focused on by researchers over the past few years. Cyclopamine, a plant-derived alkaloid with natural antagonism against SMO, was the first anti-SHh drug successfully tested to inhibit growth of some lung, SNC and prostate cancer models, both in vitro and in vivo (Vestergaard et al., 2006; Bar et al., 2007; Mimeault et al., 2010). In line with the CSC theory, these studies describe the contribution of SHh to the initiation and expansion of aberrant cell subsets of poorly differentiated, clonogenic progenitors underlying renewal and growth of the respective tumor burdens. An interesting study, performed on both MM cell lines and patients' BM specimens, revealed the occurrence of MM tumor stem cells expressing higher levels of SHh pathway components than their more differentiated counterpart. In addition, this study showed that inhibition of SHh by cyclopamine selectively impairs the function of MM CSCs in terms of clonogenic potential, while enhancing their tendency to differentiate (Peacock et al., 2007). Thus, cyclopamine may provide a useful therapeutic approach in humans and may be primarily considered as a helpful tool to verify the CSC hypothesis in MM.

Therapeutic agent	Mechanism of action	Biologic effect	References
Cyclopamine	Hh pathway antagonism	Apoptosis	<i>Peacock et al., 2007</i>
GRN163L (Imetelstat)	Telomerase inhibition	Telomere shortening Cell cycle arrest Apoptosis	<i>Shammas et al., 2008</i> <i>Brennan et al., 2010</i>
Rosiglitazone	PPAR γ binding	Cell cycle arrest	<i>Huang et al., 2009</i>
Retinoic acid	RAR binding	Cell differentiation	
Rituximab	CD20 targeting	Growth inhibition Apoptosis	<i>Matsui et al., 2008</i>

Abbreviations: Hh: Hedgehog; PPAR γ : Peroxisome proliferator-activated receptor gamma; RAR: Retinoic acid receptor

Tab. 1. List of potential therapeutic agents targeting CSCs in MM

At present, the first trial aimed at defining the anti-cancer effects of SHh inhibition in humans included GDC-0449, a small-molecule inhibitor with a mechanism of action similar to cyclopamine, that showed a significant therapeutic effect in 55% of 33 patients with basal cell carcinoma (BCC) (Von Hoff et al., 2009). These data have been recently confirmed in subsequent studies indicating that the drug exerts a considerable though variable anti-tumor effect in patients bearing different metastasizing solid tumors such as BCC and medulloblastoma (Lorusso et al., 2011). The mutable therapeutic outcome of GDC-0449, however, may be ascribed to the lower clinical doses used with respect to in vitro preclinical studies, as well as to the high probability that both BCCs and medulloblastomas may hold mutations in their SHh pathway components (Gibson et al., 2010). Nevertheless, most human cancers, including MM, have been found to accumulate no SHh pathway mutations, thus providing the rationale for testing GDC-0449 in novel clinical studies. On the other hand, distinct agents targeting SMO or other components of the SHh signalling pathways,

such as the GLI transcription factors (Gould et al., 2011; Hyman et al., 2009), may provide alternative strategies to target CSCs in experimental tumor models, including MM (Fig. 5).




Fig. 5. Preclinical agents targeting Hedgehog signalling pathway

The first step of Hedgehog (Hh) pathway activation, that is the binding of Hh ligands (Sonic, Desert and Indian) to the receptor patched 1 (PTCH1), includes the activation of the transmembrane protein smoothed (SMO), which in turn enables the release from the SMO protein complex, including the Costal (COS) and Suppressor of fused (SuFu) proteins, of GLI 1 and GLI 2 proteins, which translocate to the nucleus where they activate the transcription of major cell cycle regulator genes (Cyclin D, Cyclin E, Myc). Novel agents inhibiting the Hh signalling pathway include natural compounds such as Cyclopamine which targets SMO, and other small synthetic molecules. Among these, Robotnikinin targets the extracellular Sonic ligand, GDC-0449 inhibits SMO activation, whereas the Hh Protein Inhibitors (HPI) 1-4 interfere with the SMO-dependent activation of GLI proteins or with their nuclear translocation.

2.2.2 Inhibition of CSC telomerase activity

Similarly to most human tumor cells (Kim et al., 1994), myeloma cells express high levels of telomerase activity (Wu et al., 2003) that correlate with both disease severity and prognosis (Shiratsuchi et al., 2002). Several *in vitro* and *in vivo* studies, in fact, demonstrate that the inhibition of telomerase activity in MM cells considerably affects their survival and growth (Shammas et al., 2004). In fact, the new-generation telomerase inhibitor GRN163L

(Imetelstat), used either alone or in combination with Hsp90 inhibitor 17AAG, exerts a powerful apoptotic effect on MM cells both *in vitro* and in a mouse model of MM (Shammas et al., 2008). Moreover, identification of high telomerase activity as a MM CSC requirement to self-renewal and clonal expansion may represent a new rationale for evaluating the effect of Imetelstat in this tumor. Interestingly, long-term treatment with Imetelstat induces progressive reduction of telomere length in MM CSCs, resulting in a consistent inhibition of their capacity to form colonies *in vitro* as well as of their engraftment into immunodeficient mice. On the other hand, shorter incubation of these cells with the drug dramatically impairs their clonogenic growth, although this effect is apparently not mediated by significant shortening of the telomere length, but by a differentiation-dependent mechanism (Brennan et al., 2010). These findings provide the experimental proof that telomerase inhibiting strategies are useful anti-CSC therapeutics in MM. However, further studies are necessary to elucidate the molecular mechanisms of the telomerase inhibitors in MM CSCs.

2.2.3 Induction of CSC differentiation

Emerging evidences support the perspective that induction of CSC differentiation may provide a valid alternative to induce stem cell clone exhaustion within tumors. In a variety of solid and hematologic cancers, in fact, treatment with molecules involved in the stem cell maturation have been shown to exert significant inhibition of tumor growth (Garg, 2009). For instance, retinoic acid is well known to induce a therapeutic “differentiation syndrome” in acute promyelocytic leukemia (Rogers & Yang, 2011), whereas bone morphogenetic proteins have been shown to exert similar effect on brain CSCs, thus restraining their tumorigenic potential (Chirasani et al., 2010). Also, certain chemical compounds have been experienced as anti-cancer therapeutics due to their pro-differentiation potential. The anti-inflammatory acetaminophen, for example, has been found to induce both morphologic and functional differentiation of breast CSCs, and to impair their tumor-initiating ability *in vivo* (Takehara et al., 2011).

Recent observation strengthens the correlation between the differentiation and anti-tumor activity exerted *in vitro* by molecules as rosiglitazone and retinoic acid in MM (Huang et al., 2009). These data, moreover, are conceptually in line with previous observations that terminal differentiation of MM cells, triggered by interferon-alpha in association with interleukin-6, results in both arrest at G1 cell cycle phase and impairment of their clonogenic proliferation (Matsui et al., 2003). Therefore, the CSC hypothesis further supports the rationale for clinical differentiation therapy in MM. Inhibition of MM CSC developmental pathways or telomerase activity by specific compounds results in a down-modulation of genes involved in maintaining CSCs in undifferentiated state (Peacock et al., 2007), although further studies are needed to elucidate the specific mechanisms of action of this therapy. On the other hand, the findings that gene expression in myeloma tumor cells is highly regulated by epigenetic modifications driving their proliferation, differentiation and survival (Sharma et al., 2010), have supported the development of new therapeutic strategies. For instance, histone deacetylase and DNA methylation inhibitors are under intensive investigation as potential tools to counterbalance epigenetic, rather than genetic, modifications in both cancer cells and CSCs (Kim et al., 2011; Zhang et al., 2010; Hagemann et al., 2011). Several *in vitro* and *in vivo* studies have achieved encouraging data regarding the usefulness of epigenetic therapies in MM (Niesvizky et al., 2011), although no experimental data so far have focused their potential in eradicating MM CSCs.

Novel therapeutic perspectives against CSCs have stemmed from the observation that certain types of cancer possess specific microRNA expression patterns, and that microRNAs (miRNAs) are crucially involved in the regulation of stem cell differentiation even by modulating *OCT4*, *NANOG* and *SOX2* coding sequences (Hatfield & Ruohola-Baker, 2008; Santarpia et al., 2009). In fact, the targeting of specific miRNAs has been shown to effectively antagonize growth of glioma CSCs (Moore & Zhang, 2010), whereas the therapeutic use of miRNA inhibiting specific cellular mRNAs such as Notch-1 and -2, resulted in glioma stem cell differentiation (Guessous et al., 2010). A recent study exploring the miRNA expression patterns in patients with MM, showed that selected miRNAs were specifically altered in patients as compared to healthy subjects and, in particular, miRNA-15a and -16 exerted interesting anti-MM activity both in vitro and in vivo (Roccaro et al., 2009).

2.2.4 Alternative molecular targets of MM CSCs

Additional cellular mechanisms may account for the drug resistance of MM CSCs, thus providing new potential therapeutic targets. Several processes, such as increased DNA-repairing capacity, alteration of cell cycle checkpoints, overexpression of ABC transporters and functional defects of apoptotic pathways, have been suspected to influence the CSC biology, although very little is known on their relative contribution to MM CSC biology and no data concerning their usefulness as therapeutic targets are currently available.

A special interest is presently being reserved for developing strategies to induce death by apoptosis in CSCs. Different natural human proteins involved in immunosurveillance have been shown to trigger apoptosis in a wide variety of tumor cell types (Abe et al., 2000) and, particularly, the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was demonstrated to promptly induce apoptosis in CSCs from a few solid tumors (Loebinger et al., 2010; Sussman et al., 2007). New experimental data, however, indicate that CSCs are mostly resistant to TRAIL-induced apoptosis as a consequence of their deregulated apoptotic machinery. TRAIL effectively kills differentiated myeloma cells (Labrinidis et al., 2009), but little is known concerning the sensitivity of MM CSCs to the apoptosis inducer. In this context, only a single report has shown that these cells display both minor levels of TRAIL receptors and TRAIL resistance in vitro. However, the combinatory treatment with Doxorubicin dramatically enhances their sensitivity to the ligand, resulting in complete and lasting eradication of tumor cells in a mouse model of MM (Vitovski et al., 2011).

On the other hand, recent data emphasize the central role of microenvironmental factors, such as stromal cytokines and chemokines, neovascularization and oxygen tensions, in ensuring survival, differentiation and chemoresistance of CSCs within their “niche” (Borovski et al., 2011). Therefore, targeting the major components of the “CSC niche”, at both cellular and molecular level, is an attractive perspective to eradicate CSCs, with particular regard to MM whose development and progression are mediated by tight interactions between malignant cells and tumor microenvironment. As a matter of fact, MM CSCs isolated from both cell lines and patient BM samples have been shown to display high expression and functional activity of ABCG2 transporter and, interestingly, increase their viability and tumorigenic potential when co-cultured with bone marrow stromal cells (BMSC). In this single study, moreover, treatment with Lenalidomide exerted a significant reduction of both viability and clonogenicity of MM CSCs, and this effect was particularly evident in CSCs co-cultured with BMSCs. These data emphasize the role of stromal environment in the maintenance of MM CSC compartment and suggest that

immunomodulatory compounds disabling interactions between CSCs and their niche are potential therapeutic tools to eradicate CSCs in MM (Jakubikova et al., 2011).

3. Conclusion

New evidence emphasizes the hypothesis that circulating CBCs with clonogenic potential and properties similar to normal memory B cells are pathogenetically relevant in MM and may be considered tumor stem cells in this malignancy. To investigate this, based on the assumption that putative MM stem cells express markers of normal B cell development, including CD19 and CD20 molecules, two clinical trials have been aimed at evaluating the efficacy of the anti-CD20 monoclonal antibody Rituximab in MM patients, but, beyond the expected reduction of circulating B cells, no curative effect was observed, suggesting that this therapy fails to eradicate the self-renewing tumor cell fraction in MM (Treon et al., 2002; Zojer et al., 2006). Moreover, though the development of drug resistance in MM CSCs is favoured by the BM environment, which may account for the clinical uselessness of Rituximab (Basak et al., 2009), these preclinical results are in line with early studies suggesting that all clonal malignant plasma cells are highly capable of self-renewal in vitro as well as initiating MM growth in vivo (Yaccoby et al., 1998).

In addition, other experimental studies clearly deny the existence of clonotypic MM B cells as an effect of the absence of similar genetic alterations between B cells and tumor plasma cells in MM patients (McSweeney et al., 1996). Therefore, there is no definitive proof that these B cells compose the tumor-propagating compartment in MM and, similarly to other human cancers (Dalerba et al., 2007; O'Brien et al., 2007), several questions concerning their exact phenotype remain unanswered.

The discrepancies in the MM CSC phenotype include the excessive variability of cell isolation methods used by different research groups, whether based on positive or negative selections or on the derivation of tumor cells from BM or peripheral blood. In addition, both the clinical stage of individual patients and any previous treatments may also affect the biology of isolated MM cells and their tumorigenic precursors. Not only the discrepancies in defining the exact phenotype of MM CSCs, but also conflicting results on their functional properties have contributed to generate skepticism in the scientific community regarding the real existence of stem cells in this disease. The clonogenic potential of putative MM stem cells has been examined by a variety of both in vitro and in vivo assays, and different types of MM mouse models have been used to assess the self-renewing capacity of CSCs, thus resulting in potential discrepancies among experimental results from different research groups. Particularly in the in vivo experimental approaches, distinctly different modalities and sites of cell injection, as well as the different microenvironmental factors among the different MM animal models, may profoundly impact on the ability of specific cell types to home, survive, grow and self-renew in vivo, thus reflecting the inconsistency of the results. Therefore, improvements in discriminating both advantages and limitations of the specific assays used to assess the phenotype and the functional properties of MM CSCs are necessary, so that they can provide important knowledge in defining their actual role in MM biology.

At the same time, new clinical strategies aimed at achieving long-term outcomes in MM patients should be based on the current knowledge in the biology of CSCs, and one of the major challenges of clinicians and researchers involved in the field of MM CSCs will hopefully be the translation of the CSC theory into a clinical evaluation of the efficacy of

novel anti-MM therapeutics. In fact, the development of new agents targeting MM CSCs to be used in combination with both conventional and new-generation compounds represents a useful tool to test the CSC hypothesis in this tumor and obtain relevant results for many other types of cancer.

4. Acknowledgment

This work was supported in part by the Italian Association of Cancer Research (AIRC) and Ministero Istruzione Università e Ricerca PRIN 2008.

5. References

- Abe K, Kurakin A, Mohseni-Maybodi M, Kay B & Khosravi-Far R. (2000). The complexity of TNF-related apoptosis-inducing ligand. *Ann N Y Acad Sci*, Vol.926, pp.52-63
- Abounader R. (2010). MicroRNA-34a is tumor suppressive in brain tumors and glioma stem cells. *Cell Cycle*, Vol.9, No.6 pp-1031-1036
- Agarwal JR & Matsui W. (2010). Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. *Anticancer Agents Med Chem*, Vol.10, No.2, pp.116-120
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ & Clarke MF. (2003). Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci USA*, Vol.100, No.7, pp.3983-3988
- Anderson KC & Carrasco RD. (2011). Pathogenesis of myeloma. *Annu Rev Pathol*, Vol.28, No.6, pp.249-274
- Bakkus MH, Van Riet I, Van Camp B & Thielemans K. (1994). Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. *Br J Haematol*, Vol.87, No.1, pp.68-74
- Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A & Eberhart CG. (2007). Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. *Stem Cells*, Vol.25, No.10, pp.2524-2533
- Basak GW, Srivastava AS & Malhotra R, Carrier E. (2009). Multiple myeloma bone marrow niche. *Curr Pharm Biotechnol*. Vol.10, No.3, pp.345-346
- Bensinger WI. (2002). Allogeneic hematopoietic cell transplantation for multiple myeloma. *Biomed Pharmacother*, Vol.56, No.3, pp.133-138
- Berenson JR, Vescio RA, Hong CH, Cao J, Kim A, Lee CC, Schiller G, Berenson RJ & Lichtenstein AK. (1995). Multiple myeloma clones are derived from a cell late in B lymphoid development. *Curr Top Microbiol Immunol*, Vol.194, pp.25-33
- Bergsagel DE & Valeriote FA. (1968). Growth characteristics of a mouse plasma cell tumor. *Cancer Res*, Vol.28, No.11, pp.2187-2196
- Bergsagel PL, Smith AM, Szczepek A, Mant MJ, Belch AR & Pilarski LM. (1995). In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. *Blood*, Vol.85, No.2, pp.436-447
- Billadeau D, Ahmann G, Greipp P & Van Ness B. (1993). The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. *J Exp Med*, Vol.178, No.3, pp.1023-1031

- Bonnet D & Dick JE. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med*, Vol.3, No.7, pp.730-737
- Borovski T, De Sousa E Melo F, Vermeulen L & Medema JP. (2011). Cancer stem cell niche: the place to be. *Cancer Res*, Vol.71, No.3, pp.634-639
- Brennan SK, Wang Q, Tressler R, Harley C, Go N, Bassett E, Huff CA, Jones RJ & Matsui W. (2010). Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. *PLoS One*, Vol.5, No.9, e12487
- Brueckner B. (2011). Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. *PLoS One*, Vol.6, No.3, e17388
- Chen BJ & Epstein J. (1996). Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. *Blood*, Vol.87, No.5, pp.1972-1976
- Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M & Rummel M. (2010). Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. *Clin Lymphoma Myeloma Leuk*, Vol.10, No.1, pp.21-27
- Chirasani SR, Sternjak A, Wend P, Momma S, Campos B, Herrmann IM, Graf D, Mitsiadis T, Herold-Mende C, Besser D, Synowitz M, Kettenmann H & Glass R. (2010). Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumorigenicity of stem-like glioblastoma cells. *Brain*, Vol.133, No.7, pp.1961-1972
- Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL & Wahl GM. (2006). Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. *Cancer Res*, Vol.66, No.19, pp.9339-9344
- Dalerba P, Cho RW & Clarke MF. (2007). Cancer stem cells: models and concepts. *Annu Rev Med*, Vol.58, pp.267-284
- Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, Veelken H, Engelhardt M, Mertelsmann R, Kelleher JF, Schultz P & Warmuth M. (2007). Essential role of stromally induced hedgehog signaling in B-cell malignancies. *Nat Med*, Vol.13, No.8, pp.944-951
- Drewinko B, Alexanian R, Boyer H, Barlogie B & Rubinow SI. (1981). The growth fraction of human myeloma cells. *Blood*, Vol.57, No.2, pp.333-338
- Duman-Scheel M, Weng L, Xin S & Du W. (2002). Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. *Nature*. Vol.16, No.417, pp.299-304
- Fletcher JL, Haber M, Henderson MJ & Norris MD. (2010). ABC transporters in cancer: more than just drug efflux pumps. *Nat Rev Cancer*, Vol.10, No.2, pp.147-156
- Gailani MR, Leffell DJ, Ziegler A, Gross EG, Brash DE & Bale AE. (1996). Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. *J Natl Cancer Inst*, Vol.88, No.6, pp.349-354
- Garg M. (2009). Gain of antitumor functions and induction of differentiation in cancer stem cells contribute to complete cure and no relapse. *Crit Rev Oncog*, Vol.15, No.1, pp.57-78
- Gibson P, Tong Y, Robinson G, Thompson MC, Curre DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei Y, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA,

- Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, Ellison DW, Wechsler-Reya R & Gilbertson RJ. (2010). Subtypes of medulloblastoma have distinct developmental origins. *Nature*, Vol.468, No.7327, pp.1095-1099
- Goodell MA, Brose K, Paradis G, Conner AS & Mulligan RC. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. *J Exp Med*. Vol.183, No.4, pp.1797-1806
- Gould A & Missailidis S. (2011). Targeting the Hedgehog Pathway: The Development of Cyclopamine and the Development of Anti-Cancer Drugs Targeting the Hedgehog Pathway. *Mini Rev Med Chem*, Vol.11, No.3, pp. 200-213
- Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, Purow B, Gould T & Missailidis S. (2011). microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. *Cell Cycle*, Vol.9, No.6, pp. 1031-1036
- Hagemann S, Heil O, Lyko F & Brueckner B. (2011). Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. *PLoS One*, Vol.6, No.3, e17388
- Hamburger A & Salmon SE. (1977). Primary bioassay of human myeloma stem cells. *J Clin Invest*, Vol.60, No.4, pp. 846-854
- Hatfield S & Ruohola-Baker H. (2008). MicroRNA and stem cell function. *Cell Tissue Res*, Vol.331, No.1, pp.57-66
- Huang H, Wu D, Fu J & Chen G. (2009). Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid. *Leuk Lymphoma*, Vol.50, No.6, pp.966-973
- Hyman JM, Firestone AJ, Heine VM, Zhao Y, Ocasio CA, Han K, Sun M, Rack PG, Sinha S, Wu JJ, Solow-Cordero DE, Jiang J, Rowitch DH & Chen JK. (2009). Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. *Proc Natl Acad Sci USA*, Vol.106, No.33, pp. 14132-14137
- Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujovala D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC & Mitsiades CS. (2011). Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. *Blood*, Vol.117, No.17, pp. 4409-4419
- Jamieson CH, Weissman IL & Passegué E. (2004). Chronic versus acute myelogenous leukemia: a question of self-renewal. *Cancer Cell*, Vol.6, No.6, pp.531-533
- Jensen GS, Mant MJ, Belch AJ, Berenson JR, Ruether BA & Pilarski LM. (1991). Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. *Blood*, Vol.78, No.3, pp.711-719
- Jensen GS, Belch AR, Mant MJ, Ruether BA & Pilarski LM. (1992). Expression of multiple adhesion molecules on circulating monoclonal B cells in myeloma. *Curr Top Microbiol Immunol*, Vol.182, pp.187-193
- Jensen GS, Mant MJ & Pilarski LM. (1992). Sequential maturation stages of monoclonal B lineage cells from blood, spleen, lymph node, and bone marrow from a terminal myeloma patient. *Am J Hematol*, Vol.41, No.3, pp.199-208
- Johnson K, Shapiro-Shelef M, Tunyaplin C & Calame K. (2005). Regulatory events in early and late B-cell differentiation. *Mol Immunol*, Vol.42, No.7, pp.749-761
- Kim HJ & Bae SC. (2011). Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. *Am J Transl Res*, Vol.3, No.2, pp.166-179

- Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL & Shay JW. (1994). Specific association of human telomerase activity with immortal cells and cancer. *Science*, Vol.266, No.5193, pp.2011-2015
- Koreth J (2007). High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. *Biol Blood Marrow Transplant*, Vol.13, No.2, pp.183-196
- Kyle RA & Rajkumar SV. (2004). Multiple myeloma. *N Engl J Med*, Vol.351, No.18, pp.1860-1873
- Labrinidis A, Diamond P, Martin S, Hay S, Liapis V, Zinonos I, Sims NA, Atkins GJ, Vincent C, Ponomarev V, Findlay DM, Zannettino AC & Evdokiou A. (2009). Apo2L/ TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. *Clin Cancer Res*, Vol.15, No.6. pp.1998-2009
- Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA & Dick JE. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature*, Vol.367, No.6464, pp.645-648
- Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P & Wicha MS. (2006). Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. *Cancer Res*, Vol.66, No.12, pp.6063-6071
- Loebinger MR, Sage EK, Davies D & Jones SM. (2010). TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. *Br J Cancer*, Vol.103, No.11, pp.1692-1697
- Lonial S, Mitsiades CS & Richardson PG. (2011). Treatment options for relapsed and refractory multiple myeloma. *Clin Cancer Res*, Vol.17, No.6, pp.1264-1277
- Lorusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low J & Von Hoff DD. (2011). Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. *Clin Cancer Res*, Vol.17, No.8, pp. 2502-2511
- Matsui W, Huff CA, Vala M, Barber J, Smith BD & Jones RJ (2003). Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation. *Br J Haematol*, Vol.21, No.2, pp.251-258
- Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI & Jones RJ (2004). Characterization of clonogenic multiple myeloma cells. *Blood*, Vol.103, No.6, pp.2332-2336
- Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA & Jones RJ (2008). Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. *Cancer Res*. Vol.68, No.1, pp.190-197
- McSweeney PA, Wells DA, Shults KE, Nash RA, Bensinger WI, Buckner CD & Loken MR. (1996). Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. *Blood*, Vol.88, No.2, pp.622-632
- Mimeault M, Johansson SL, Henichart JP, Depreux P & Batra SK. (2010). Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. *Mol Cancer Ther*, Vol.9, No.3, pp.617-630

- Moore LM & Zhang W. (2010). Targeting miR-21 in glioma: a small RNA with big potential. *Expert Opin Ther Targets*, Vol.14, No.11, pp.1247-1257
- Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Schöler H & Smith A. (1998). Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell*, Vol.95, No.3, pp.379-391
- Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, Chen-Kiang S & Sparano JA. (2011). Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. *Cancer*, Vol.117, No.2, pp.336-342
- O'Brien CA, Pollett A, Gallinger S & Dick JE. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature*, Vol.445, No.7123, pp.106-110
- Oken MM. (1997). Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. *Cancer*, Vol.79, No.8, pp.1561-1567
- Park CH, Bergsagel DE & McCulloch EA. (1971). Mouse myeloma tumor stem cells: a primary cell culture assay. *J Natl Cancer Inst*, Vol.46, No.2, pp.411-422
- Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J, Devereux WL, Rhodes JT, Huff CA, Beachy PA, Watkins DN & Matsui W. (2007). Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. *Proc Natl Acad Sci USA*, Vol.104, No.10, pp.4048-4053
- Pilarski LM & Jensen GS. (1992). Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. *Hematol Oncol Clin North Am*, Vol.6, No.2, pp.297-322
- Pilarski LM & Belch AR. (1994). Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. *Blood*, Vol.83, No.3, pp.724-736
- Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW & Belch AR. (2000). Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. *Blood*, Vol.95, No.3, pp.1056-1065
- Pilarski LM & Belch AR. (2002). Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. *Clin Cancer Res*, Vol.8, No.10, pp.3198-3204
- Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, Fults DW & James CD. (1997). Sporadic medulloblastomas contain PTCH mutations. *Cancer Res*, Vol.57, No.5, pp.842-845
- Rasmussen T, Lodahl M, Hancke S & Johnsen HE. (2004). In multiple myeloma clonotypic CD38- / CD19+ / CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. *Leuk Lymphoma*, Vol.45, No.7, pp.1413-1417
- Rasmussen T. (2001). The presence of circulating clonal CD19+ cells in multiple myeloma. *Leuk Lymphoma*, Vol.42, No.6, pp.1359-1366
- Robillard N, Pellat-Deceunynck C & Bataille R. (2005). Phenotypic characterization of the human myeloma cell growth fraction. *Blood*, Vol.105, No.12, pp.4845-4848
- Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC & Ghobrial IM.

- (2009). MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. *Blood*, Vol.113, No.26, pp.6669-6680
- Rogers JE & Yang D. (2011). Differentiation syndrome in patients with acute promyelocytic leukemia. *J Oncol Pharm Pract*, Ahead of print
- Ruiz i Altaba A, Sánchez P & Dahmane N. (2002). Gli and hedgehog in cancer: tumours, embryos and stem cells. *Nat Rev Cancer*, Vol.2, No.5, pp.361-372
- Santarpia L, Nicoloso M & Calin GA. (2010). MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. *Endocr Relat Cancer*, Vol.17, No.1, pp.51-75
- Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, Anderson KC, Chin A, Gryaznov S & Munshi NC. (2008). Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. *Leukemia*, Vol.22, No.7, pp.1410-1418
- Shammas MA, Shmookler Reis RJ, Li C, Koley H, Hurley LH, Anderson KC & Munshi NC. (2004). Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. *Clin Cancer Res*, Vol.10, No.2, pp.770-776
- Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Greally JM & Verma A. (2010). DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. *Wiley Interdiscip Rev Syst Biol Med*, Vol.2, No.6, pp.654-669
- Shay JW & Bacchetti S. (1997). A survey of telomerase activity in human cancer. *Eur J Cancer*. Vol.33, No.5, pp.787-791
- Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, Takatsuki H, Uike N, Umemura T, Nawata H & Nishimura J. (2002). Clinical significance of telomerase activity in multiple myeloma. *Cancer*, Vol.94, No.8, pp.2232-2238
- Singh SK, Clarke ID, Hide T & Dirks PB. (2004). Cancer stem cells in nervous system tumors. *Oncogene*, Vol.23, No.43, pp.7267-7273
- Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD & Dirks PB. (2004). Identification of human brain tumour initiating cells. *Nature*, Vol.432, No.7015, pp.396-401
- Sussman RT, Ricci MS, Hart LS, Sun SY & El-Deiry WS. (2007). Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. *Cancer Biol Ther*, Vol.6, No.9, pp.1490-1495
- Szcepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR & Pilarski LM. (1998). A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. *Blood*, Vol.92, No.8, pp.2844-2855
- Taipale J & Beachy PA. (2001). The Hedgehog and Wnt signalling pathways in cancer. *Nature*, Vol.411, No.6835, pp.349-354
- Takehara M, Hoshino T, Namba T, Yamakawa N & Mizushima T. (2011). Acetaminophen-induced differentiation of human breast cancer stem cells and inhibition of tumor xenograft growth in mice. *Biochem Pharmacol*, Vol.81, No.9, pp. 1124-1135
- Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szcepek AJ, Ellman L, Harmon D, Grossbard ML & Anderson KC. (2002). CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. *J Immunother*, Vol.25, No.1, pp.72-81

- Vestergaard J, Pedersen MW, Pedersen N, Ensinger C, Tümer Z, Tommerup N, Poulsen HS & Larsen LA. (2006). Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. *Lung Cancer*, Vol.52, No.3, pp.281-290
- Visvader JE. (2011). Cells of origin in cancer. *Nature*. Vol.469, No.7330, pp.314-322
- Vitovski S, Chantry AD, Lawson MA & Croucher PI. (2011). Targeting tumour-initiating cells with trail based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. *Bone*, Abstract
- Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ & Low JA. (2009). Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N Engl JMed*, Vol.361, No.12, pp.1164-1172
- Wu KD, Orme LM, Shaughnessy J Jr, Jacobson J, Barlogie B & Moore MA. (2003). Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. *Blood*. Vol.101, No.12, pp.4982-4989
- Yaccoby S, Barlogie B & Epstein J (1998). Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. *Blood*, Vol.92, No.8, pp.2908-2913
- Yaccoby S & Epstein J (1999). The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. *Blood*, Vol.94, No.10, pp.3576-3582
- Yaccoby S. (2005). The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. *Clin Cancer Res*, Vol.11, No.21, pp.7599-7606
- Yu HB, Kunarso G, Hong FH & Stanton LW. (2009). Zfp206, Oct4, and Sox2 are integrated components of a transcriptional regulatory network in embryonic stem cells. *JBiol Chem*, Vol.284, No.45, pp.31327-31335
- Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD, Snyder DS, Huettner CS, Shultz L, Holyoake T & Bhatia R. (2010). Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. *Cancer Cell*, Vol.17, No.5, pp.427-442
- Zhang S, Suvannasankha A, Crean CD, White VL, Chen CS & Farag SS. (2010). The novel histone deacetylase inhibitor, AR-42, inhibits gp130/ Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells. *Int JCancer*, Vol.129, No.1, pp. 204-213
- Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, VanArsdale T, Beachy PA & Reya T. (2009). Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. *Nature*, Vol.458, No.7239, pp.776-779
- Zojer N, Kirchbacher K, Vesely M, Hübl W & Ludwig H. (2006). Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. *Leuk Lymphoma*, Vol.47, No.6, pp.1103-1109



Cancer Stem Cells - The Cutting Edge

Edited by Prof. Stanley Shostak

ISBN 978-953-307-580-8

Hard cover, 606 pages

Publisher InTech

Published online 01, August, 2011

Published in print edition August, 2011

Over the last thirty years, the foremost inspiration for research on metastasis, cancer recurrence, and increased resistance to chemo- and radiotherapy has been the notion of cancer stem cells. The twenty-eight chapters assembled in *Cancer Stem Cells - The Cutting Edge* summarize the work of cancer researchers and oncologists at leading universities and hospitals around the world on every aspect of cancer stem cells, from theory and models to specific applications (glioma), from laboratory research on signal pathways to clinical trials of bio-therapies using a host of devices, from solutions to laboratory problems to speculation on cancer's stem cells' evolution. Cancer stem cells may or may not be a subset of slowly dividing cancer cells that both disseminate cancers and defy oncotoxic drugs and radiation directed at rapidly dividing bulk cancer cells, but research on cancer stem cells has paid dividends for cancer prevention, detection, targeted treatment, and improved prognosis.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Sabino Ciavarella, Annalisa Milano, Annalisa Savonarola, Oronzo Brunetti, Franco Dammacco and Franco Silvestris (2011). *Cancer Stem Cells in Multiple Myeloma*, *Cancer Stem Cells - The Cutting Edge*, Prof. Stanley Shostak (Ed.), ISBN: 978-953-307-580-8, InTech, Available from: <http://www.intechopen.com/books/cancer-stem-cells-the-cutting-edge/cancer-stem-cells-in-multiple-myeloma>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License](#), which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.

IntechOpen

IntechOpen